Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.020 AlteredExpression disease BEFREE SCARA3 messenger RNA (mRNA) expression was analyzed in 127 effusions (103 ovarian/peritoneal/fallopian tube carcinomas, 9 breast carcinomas, 15 malignant mesotheliomas [MM]), and 30 solid primary OCs. 21855113 2012
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.020 AlteredExpression phenotype BEFREE Survival analysis indicated that methylation of the CSR1 promoter, and to a lesser extent down-regulation of CSR1 protein expression, was associated with a high rate of prostate cancer metastasis. 16436673 2006
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.020 AlteredExpression phenotype LHGDN Survival analysis indicated that methylation of the CSR1 promoter, and to a lesser extent down-regulation of CSR1 protein expression, was associated with a high rate of prostate cancer metastasis. 16436673 2006
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.020 AlteredExpression phenotype BEFREE Expression of CSR1 in PC3 cell xenografts produced a dramatic reduction (>8-fold) in tumor size, rate of invasion (0 versus 31%), and mortality (13 versus 100%). 16436673 2006
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.020 AlteredExpression disease BEFREE They therefore suggest that dysregulation of APC activity, possibly through downregulation of APC7, may be associated with tumorigenesis in breast cancer. 15743504 2005
CUI: C0040100
Disease: Thymoma
Thymoma
0.010 AlteredExpression disease BEFREE At quantitative assessment, both the radiodensity and CSR were significantly higher for thymoma compared with nonthymoma groups (<i>P</i> < .001). 31331197 2020
CUI: C0008039
Disease: Cheyne-Stokes Respiration
Cheyne-Stokes Respiration
0.010 GeneticVariation phenotype BEFREE Background The contribution of the lung or the plant gain ( PG ; ie, change in blood gases per unit change in ventilation) to Cheyne-Stokes respiration ( CSR ) in heart failure has only been hypothesized by mathematical models, but never been directly evaluated. 31237174 2019
CUI: C0018572
Disease: Hand, Foot and Mouth Disease
Hand, Foot and Mouth Disease
0.010 Biomarker disease BEFREE The mean relative expression levels in severe HFMD and control HFMD patients were 10.1-fold and 5.0-fold, respectively, P value <.001.We found that SCARA3 is associated with severity of HFMD, and it may be a potential prognostic marker to predict the HFMD progression in EV71 infected patients. 31577778 2019
CUI: C3897752
Disease: Recurrent Childhood Glioblastoma
Recurrent Childhood Glioblastoma
0.010 GeneticVariation disease BEFREE In this phase I clinical study, we evaluated the safety and bioactivity of CSR-T cell therapy in 14 patients with recurrent glioblastoma who were unresponsive to surgical resection and standard radiotherapy. 31136972 2019
CUI: C4288305
Disease: Recurrent Glioblastoma
Recurrent Glioblastoma
0.010 GeneticVariation disease BEFREE In this phase I clinical study, we evaluated the safety and bioactivity of CSR-T cell therapy in 14 patients with recurrent glioblastoma who were unresponsive to surgical resection and standard radiotherapy. 31136972 2019
CUI: C0027059
Disease: Myocarditis
Myocarditis
0.010 Biomarker disease BEFREE Patients with myocarditis showed significantly reduced LA passive strain (LA ε<sub>e</sub>: 26.3 ± 14.5 vs. 33.5 ± 10.1%, p = .007), LA peak early negative strain rate (LA SRe: -1.94 ± 0.59 1/s vs. -1.46 ± 0.62 1/s, p < .001), LV global longitudinal strain (LV GLS: -17.2 ± 4.9% vs. -13.3 ± 6.2%, p < .001), LV midventricular circumferential strain (LV mid CS: -25.9 ± 4.7% vs. -22.0 ± 6.5%, p < .001), and an increased RV basal circumferential SR (RV basal CSR: -0.70 ± 028 vs. -0.58 ± 0.34 1/s, p = .096) compared to healthy controls. 29857857 2018
CUI: C0278704
Disease: Malignant Childhood Neoplasm
Malignant Childhood Neoplasm
0.010 GeneticVariation disease BEFREE In 22 childhood cancer survivors (median age: 14.8, range 6.4-21.6 years), mean GLS (- 13.83 ± 0.74% to - 15.94 ± 0.74%, p = 0.002), GCS (- 18.79 ± 1.21% to - 20.74 ± 0.84%, p = 0.027), LSR (- 0.78 ± 0.04 to - 0.88 ± 0.04 s<sup>-1</sup>, p = 0.022), and CSR (- 1.08 ± 0.07 to - 1.21 ± 0.06 s<sup>-1</sup>, p = 0.027) improved on therapy. 29789916 2018
CUI: C0030193
Disease: Pain
Pain
0.010 Biomarker phenotype BEFREE Knowledge of this abnormal FC might lead to a better understanding of the mechanism underlying CNSP-CSR, especially the descending pain modulation system involved in chronic pain. 28574927 2017
CUI: C1285498
Disease: Vegetation
Vegetation
0.010 GeneticVariation disease BEFREE We measured 16 different functional traits and then ordinated the resulting vegetation within the CSR triangle using StrateFy. 28388622 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.010 AlteredExpression disease BEFREE The mRNA and protein levels of CSR1 were down-regulated in human HCC cell lines and clinic HCC tissues. 28975986 2017
CUI: C1449563
Disease: Cardiomyopathy, Familial Idiopathic
Cardiomyopathy, Familial Idiopathic
0.010 Biomarker disease BEFREE We aimed to explore the prevalence of polymorphisms of the HSPB7 gene in the Chinese Han population with CSR-CSA and CHF caused by DCM. 27441470 2016
CUI: C0010278
Disease: Craniosynostosis
Craniosynostosis
0.010 GeneticVariation disease BEFREE Here, we describe a patient whose features we would suggest represent a new FGFR2-related syndrome, craniosynostosis with XY male-to-female sex reversal or CSR. 26362256 2015
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.010 Biomarker disease BEFREE In MM, SCARA3 protects against oxidative stress-induced cell killing and can serve as predictor of MM progression and therapeutic response. 23537707 2013
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.010 AlteredExpression group BEFREE SCARA3 levels in effusions and primary carcinomas were unrelated to patient age, tumor grade, FIGO stage, residual tumor volume after surgery, response to chemotherapy, or survival (P > .05 for all). 21855113 2012
CUI: C0025500
Disease: Mesothelioma
Mesothelioma
0.010 AlteredExpression disease BEFREE SCARA3 messenger RNA (mRNA) expression was analyzed in 127 effusions (103 ovarian/peritoneal/fallopian tube carcinomas, 9 breast carcinomas, 15 malignant mesotheliomas [MM]), and 30 solid primary OCs. 21855113 2012
CUI: C1514428
Disease: Primary peritoneal carcinoma
Primary peritoneal carcinoma
0.010 AlteredExpression disease BEFREE Scavenger receptor class A, member 3 (SCARA3) was previously found to be overexpressed in ovarian/primary peritoneal carcinoma (OC/PPC) compared with breast carcinoma effusions by global gene expression analysis. 21855113 2012
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.010 GeneticVariation disease BEFREE Within the CSR gene set, a group of 42 v-Src inducible genes was associated with reduced disease- and metastasis-free survival in several independent patient cohorts with breast or lung cancer. 20152043 2010
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.010 GeneticVariation disease BEFREE Within the CSR gene set, a group of 42 v-Src inducible genes was associated with reduced disease- and metastasis-free survival in several independent patient cohorts with breast or lung cancer. 20152043 2010
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung
0.010 GeneticVariation disease BEFREE Within the CSR gene set, a group of 42 v-Src inducible genes was associated with reduced disease- and metastasis-free survival in several independent patient cohorts with breast or lung cancer. 20152043 2010
CUI: C0162429
Disease: Malnutrition
Malnutrition
0.010 Biomarker disease BEFREE Four Ig-CSR deficiency phenotypes have been so far reported: the description of the activation-induced cytidine deaminase (AID) deficiency (Ig-CSR deficiency 1), caused by recessive mutations of AICDA gene, characterized by a defect in CSR and SHM, clearly established the role of AID in the induction of the Ig gene rearrangements underlying CSR and SHM. 17560278 2007